Other News To Note
Thursday, July 11, 2013
Pharmacyclics Inc., of Sunnyvale, Calif., and Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said a new drug application was submitted for ibrutinib for use in previously treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia and for use in previously treated patients with mantle cell lymphoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.